Compass Therapeutics Inc. Cash Flow Conversion Efficiency
Compass Therapeutics Inc. cash flow conversion efficiency. Based on the latest financial reports, Compass Therapeutics Inc. (CMPX) has a cash flow conversion efficiency ratio of -0.081x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-13.42 Million) by net assets ($166.05 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Compass Therapeutics Inc. (CMPX) total market value for the company's overall valuation and market capitalisation.
Cash Flow Conversion Efficiency of Compass Therapeutics Inc. (2018–2025)
Cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2025. This chart illustrates how Compass Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Compass Therapeutics Inc. for real-time trading data and today's change.
Compass Therapeutics Inc. Cash Flow Conversion Ratio Explained
Compass Therapeutics Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Compass Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Compass Therapeutics Inc. ranked by their cash flow conversion efficiency. Review CMPX financial flexibility score to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Silicon Optronics Inc
TW:3530
|
0.056x |
|
Moller Y Perez
SN:MOLLER
|
-0.016x |
|
Israel Land Development Urban Renewal Ltd
TA:ILDR
|
-0.151x |
|
Heungkuk F&M I
KO:000540
|
0.097x |
|
STEEL EXCHANGE INDIA LIMITED
NSE:STEELXIND
|
-0.015x |
|
Seven West Media Ltd
AU:SWM
|
-0.001x |
|
Dat Phuong JSC
VN:DPG
|
0.059x |
|
Acusensus Ltd
AU:ACE
|
0.023x |
Annual Cash Flow Conversion Efficiency for Compass Therapeutics Inc. (2018–2025)
The table below shows the annual cash flow conversion efficiency of Compass Therapeutics Inc. from 2018 to 2025. Also see Compass Therapeutics Inc. asset portfolio for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.79 Million | $-49.14 Million | -0.250x | +30.28% |
| 2024-12-31 | $125.23 Million | $-44.85 Million | -0.358x | -30.98% |
| 2023-12-31 | $148.54 Million | $-40.62 Million | -0.273x | -45.55% |
| 2022-12-31 | $181.64 Million | $-34.12 Million | -0.188x | -33.82% |
| 2021-12-31 | $140.08 Million | $-19.67 Million | -0.140x | +79.08% |
| 2020-12-31 | $39.95 Million | $-26.80 Million | -0.671x | -350.72% |
| 2019-12-31 | $-118.60 Million | $-31.74 Million | 0.268x | -32.64% |
| 2018-12-31 | $-84.77 Million | $-33.68 Million | 0.397x | -- |
About Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tum… Read more